Drugs / REGN1908-1909
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01922661 | Aug 2013 → May 2014 | allergic disease | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT03838731 | Feb → Dec 2019 | asthma | Regeneron Pharmaceuticals | Completed | Met primary |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT04981717 | Jul 2021 → Jan 2023 | allergic rhinitis | Regeneron Pharmaceuticals | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-02-10 | Regeneron Pharmaceuticals | Results Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy regeneron.com ↗
A Single Prophylactic Dose of REGN1908-1909 Significantly Suppressed Cat-Allergen Induced Allergic Conjunctivitis Signs and Symptoms and Skin Test Reactivity |
| 2021-02-27 | Regeneron Pharmaceuticals | Results Regeneron Announces Positive Phase 2 Data Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Patients with Mild Asthma regeneron.com ↗
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced detailed results from a Phase 2 proof-of-concept trial evaluating the investigational antibody cocktail REGN1908-1909 in cat-allergic patients with mild asthma. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-02-10 | Regeneron Pharmaceuticals | Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy regeneron.com ↗ |
| 2021-02-27 | Regeneron Pharmaceuticals | Regeneron Announces Positive Phase 2 Data Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Patients with Mild Asthma regeneron.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN1908-1909 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03838731 ↗ |
| Action | Inhibit | “REGN1908-1909 monoclonal antibodies block Fel d 1 in cat allergic subjects” PMID 34437752 ↗ Aug 2021 |
| Modality | Monoclonal antibody | “REGN1908-1909, a 1:1 cocktail of two fully human IgG4 monoclonal antibodies (mAbs)” PMID 34437752 ↗ Aug 2021 |
| Route | Subcutaneous | “single subcutaneous administration of placebo (n = 6) or REGN1908-1909 at doses of 150 (n = 6), 300 (n = 6), or 600 mg (n = 6)” PMID 34437752 ↗ Aug 2021 |